Negative effects of iodine-based contrast agent on renal function in patients with moderate reduced renal function hospitalized for COVID-19

Table 2 Linear regression analysis of variables associated with a > 50% rise in P-creatinine at 48 h or 4–10 days after contrast-enhanced CT

Variable^a	Nr subjects at 48 h / Nr subjects at 4–10 days after CT	Above or below median value	P-creatinine rise 26.5 μmol/L or > 50% at 48 h after CT, OR (95% CI)	p-value	P-creatinine rise 26.5 μmol/L or > 50% and/or RRT initiation at 4–10 days after CT, OR (95% CI)	p-value
Male sex	114/93		1.2 (0.2–6)	0.86	3.0 (0.3–26)	0.25
Age (years)	114/102	> 59	2.2 (0.5–9.4)	0.27	4.7 (0.9–24)	0.042
Thromboembolic treatment	114/93		0.59 (0.1–2.6)	0.49	0.95 (0.2–5)	0.96
Renal disease	112/91		4.2 (0.4–46)	0.29	6.8 (0.5–90)	0.19
Type 2 diabetes	111/90		3.3 (0.8–14)	0.11	0.8 (0.1–7)	0.80
P-creatinine (μmol/L) at CT	114/93	> 67	1.7 (0.4–6.7)	0.46	2.4 (0.6–11)	0.22
CRP at CT scan (mg/L)	113/92	> 93	3.8 (0.7–19)	0.08	6.8 (0.8–60)	0.039
Dose/weight (ml/kg)	89/70	> 0.78	0.68 (0.14–3.3)	0.63	0.9 (0.2–3.9)	0.86
eGFR≥30–60 and contrast-enhanced CT	114/93		5.7 (1.3–24)	0.018	10.4 (2.3–47)	0.002
ICU care	113/92		2.0 (0.5–8)	0.34	5.7 (1.2–27)	0.023
30-day mortality	114/93		12 (2.7–54)	< 0.001	16 (3–79)	< 0.001
Renal replacement therapy at CT^b	128/106		4.7 (1.2–18)	0.037	5.2 (1.4–19)	0.017

^a Patients performing contrast-enhanced CT, excluding subjects on renal replacement therapy.
^b Including patients on renal replacement therapy.
CI confidence interval, CRP C-reactive protein, CT computed tomography, eGFR estimated glomerular filtration rate (ml/min × 1.73 m²), h hours, ICU intensive care unit, OR odds ratio, Nr Number, P-creatinine plasma creatinine, RRT renal replacement therapy

ISSN: 1471-2369